Post Traumatic Stress Disorder (PTSD) Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2024-2032)

Post Traumatic Stress Disorder (PTSD) Market Outlook

• The increasing cases of post traumatic stress disorder, particularly among military personnel, first responders, and trauma survivors, is driving the demand for effective treatments.
• Increased clinical research and the rise in strategic partnerships among the leading pharmaceutical companies are major market trends.
• The rising introduction of novel drugs, the growth in telehealth services and online support groups, and the increasing investment in PTSD research are anticipated to elevate the market value in the forecast period.

Post Traumatic Stress Disorder (PTSD) Market Overview

Post traumatic stress disorder (PTSD) is a mental health condition that can develop after experiencing a terrifying event. Common symptoms include flashbacks/nightmares of similar situations, severe anxiety, uncontrollable thoughts about the event, memory lapses, distorted sense of self, hyperarousal, unexplained upset stomach, and sleep disturbances, among others.

The growing demand for effective treatments is expected to stimulate research initiatives focused on understanding and addressing PTSD, creating a positive feedback loop that would further aid the growth of post traumatic stress disorder (PTSD) market. The increased dedication of researchers toward finding effective PTSD treatments is evident in various studies, exemplified by recent research results. The conclusive findings of such studies are contributing to the growing body of knowledge surrounding PTSD, fostering a deeper understanding of the condition. The rigorous efforts of the research community, coupled with the introduction of innovative therapies, are instrumental in shaping the trajectory of the PTSD market, promising a future marked by increased awareness, advanced treatment options, and sustained growth within the healthcare landscape.

Post Traumatic Stress Disorder (PTSD) Market Growth Drivers

Increasing Prevalence of Post Traumatic Stress Disorder Drives Market Growth

The prevalence of post traumatic stress disorder (PTSD) is on the rise and is significantly driving the market growth. Increasing stress and adapting to a sedentary lifestyle are the main factors that trigger the occurrence of PTSD in people. According to the National Center for PTSD, 6 out of 10 men (or 60%) and 5 of every 10 women (or 50%) experience at least one trauma in their lifetime. Thus, the increasing cases of post traumatic stress disorder, particularly among military personnel, first responders, and trauma survivors, is a primary driver of the market.

Post Traumatic Stress Disorder (PTSD) Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Increased Clinical Research to Affect the Market Landscape Significantly

Increased clinical research is a major market trend. New treatment therapies are emerging in the market, exemplified by a new study that claims that patients writing about their trauma in five supervised 30-minute sessions is as effective as the therapies recommended by federal agencies. This therapy has been named written exposure therapy. Such research studies are poised to positively influence the market dynamics.

Growth in Telehealth Services Poised to Augment Post Traumatic Stress Disorder (PTSD) Market Demand

One of the major market trends is the growth in telehealth services including teletherapy, which allows patients to connect with mental health professionals through video conferencing or phone calls. Besides removing geographical barriers to treatment access, telehealth platforms also improve appointment adherence and reduce travel-related stress.

Robust Regulatory Support to Elevate the Post Traumatic Stress Disorder (PTSD) Market Value

In June 2024 , Otsuka Pharmaceutical, Co. Ltd. (Tokyo-based pharmaceutical company) and H. Lundbeck A/S (Danish pharma giant focused on neuroscience) announced that its supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline was accepted by the U.S. Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD) in adults. Such robust regulatory support for the advancement of new treatment options is likely to elevate the market value in the coming years.

Strategic Partnerships and Collaborations to Boost Post Traumatic Stress Disorder (PTSD) Market Size

To stay ahead of the competition, market players are adopting various competitive strategies, such as mergers and acquisitions, collaborating for research and development, and developing new products. These strategies aim to develop effective antidepressant drugs and ensure the sustainability of the leading pharmaceutical companies in the market.

Post Traumatic Stress Disorder (PTSD) Market Segmentation

Market Breakup by Drug Class

• Antidepressants
• Antipsychotics
• Anti-anxiety Drugs
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Age Group

• Adult
• Geriatric

Market Breakup by End User

• Hospitals and Clinics
• Ambulatory Surgical Centers 
• Homecare Settings 
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
• Japan
• India

Post Traumatic Stress Disorder (PTSD) Market Share

Drug Class Segment is Anticipated to Witness Substantial Growth

Based on the drug class, the market is segmented into antidepressants, antipsychotics, anti-anxiety drugs, and others. Antidepressants, including SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors), are the commonly prescribed medications for post traumatic stress disorder owing to their high efficacy and better tolerability. The rising focus on R&D activities to improve existing formulations and develop new antidepressants with fewer side effects is projected to aid the growth of this segment.

Post Traumatic Stress Disorder (PTSD) Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents one of the largest markets for post traumatic stress disorder owing to the significant prevalence of this mental condition, a well-established healthcare system, and a growing focus on mental health awareness. The market also benefits from the rising adoption of telehealth platforms in the region, which allows greater access to mental health services. Moreover, increased campaigns aimed at destigmatizing PTSD and substantial funding for mental health treatments are poised to boost the market growth.

Leading Players in the Post Traumatic Stress Disorder (PTSD) Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer is one of the leading companies in the market and holds an extensive portfolio in mental health treatment. The company's popular drug Zoloft (sertraline hydrochloride) is widely used to help manage symptoms of anxiety and depression associated with PTSD.

Eli Lilly and Company

Headquartered in Indianapolis, Indiana, Eli Lilly and Company has a prominent presence in the market. The company invests heavily in clinical trials to validate new therapeutic options for PTSD patients.

Johnson & Johnson (Janssen Pharmaceuticals)

Janssen (the pharmaceutical division of Johnson & Johnson) plays a significant role in the growth of the market for post traumatic stress disorder. The company is known for its antipsychotic medications and is also engaged in researching other pharmacological options for the treatment of PTSD.

GSK plc

GSK plc, headquartered in Brentford, United Kingdom, is a leading player in the market. GSK's portfolio includes various antidepressants that help in managing PTSD symptoms.

Other key players in the market include Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company, Bristol-Myers Squibb Company, H. Lundbeck A/S, Genentech USA, Inc., and Eisai Co., Ltd., among others.

Key Questions Answered in the Post Traumatic Stress Disorder (PTSD) Market Report

• What was the post traumatic stress disorder (PTSD) market value in 2023?
• What is the post traumatic stress disorder (PTSD) market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on the drug class?
• What is the market breakup based on the route of administration?
• What is the market breakup by age group?
• Who are the major end users in the market?
• What are the major factors aiding the post traumatic stress disorder (PTSD) market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How do the prevalence and incidence of post traumatic stress disorder affect the market landscape?
• What are the major post traumatic stress disorder (PTSD) market trends?
• How does the advancement in treatment options impact the market size?
• Which drug class will dominate the market share? 
• Which route of administration is expected to have a high market value in the coming years?
• Which age group will experience the highest demand in the market segment?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the post traumatic stress disorder (PTSD) market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?